Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AbCellera Biologics Q4 2023 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $9.18M Beat $8.88M Estimate

Author: Benzinga Newsdesk | February 20, 2024 05:26pm
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. The company reported quarterly sales of $9.18 million which beat the analyst consensus estimate of $8.88 million by 3.31 percent. This is a 57.40 percent decrease over sales of $21.55 million the same period last year.

Posted In: ABCL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist